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Abstract
Background: Due to demographic transition, multimorbidity and high numbers of medicinal products,
polypharmacy rates will presumably further increase. This could lead to higher risks of potentially inappropriate
medications with potential drug-drug interactions (PDDI). PDDI has already been investigated by several studies,
but not for patients with indication for prophylactic implantation of a cardioverter defibrillator (ICD). Thus, the
objective of this analysis was to examine the frequency of PDDI in that specific group of patients and compare
patients with or without PDDI regarding potential underlying factors.
Methods: Cross-sectional data analyses were performed using data of the prospective EU-CERT-ICD study that
primarily aimed to assess ICD effectiveness in Europe. Self-reported baseline medication data of patients from
Germany and Switzerland were used. Patients who reported to take at least two drugs simultaneously for at least
80 days were defined as population at risk. By means of a publicly available interaction checker, we analyzed the
medication data regarding occurrence and characteristics of PDDI categorized as minor, moderate, and major PDDI.
The analyses were done using descriptive methods and chi square testing.
Results: The total population (n = 524) and the population at risk (n = 383) were rather similar with an average age of
64 years and about 80% male. PDDIs were found for 296 patients (in 57% of total population vs. 77% of population at
risk). The moderate PDDI category was most frequently with 268 affected patients. Comparing patients with and
without any PDDI, the proportion of patients with place of residence in Germany varied distinctly (93% vs. 78%). The
frequency of any PDDI for the total population was twice as high in Germany as in Switzerland (p value < 0.001).
Conclusions: PDDIs were frequently observed in this selected patient population and differed markedly between
German and Swiss patients. The results should lead to higher awareness of polypharmacy and PDDIs. Adequate
cooperation between health care providers should be promoted and new technologies such as drug interaction
information systems or digital patient files used.
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Background
In the context of demographic transition, associated with
a growing proportion of people aged ≥65 years, the in-
creasing frequency of chronic diseases and comorbidities
and the growing need of pharmacological treatment, the
probability of co-medication up to polypharmacy (de-
fined as five or more concurrent drugs [1]) is high and
will presumably continue to rise. An available number of
more than 100,000 drugs authorized on the German
health care market supports this assumption [2]. The
importance of the pharmaceutical market in Germany
can also be seen, among other things, in the fact that
health expenditure on drugs has almost doubled in the
last 20 years and amounted to approximately 52 billion
euros in 2017 [3].
Several studies assessed the frequency of drug use and
polypharmacy in Germany during the last years. Accord-
ing to data of the German Health Interview and Examin-
ation Survey for Adults, nearly three quarters of their
participants reported that they have taken at least one
drug or food supplement in the last 7 days [4]. A report
on drug use for insurants of a large German statutory
health insurance company supported these findings [5].
The average number of preparations differed between
insured men and women from 2.0 to 3.1. The frequency
of a prescribed polypharmacy was 13.6% in women and
9.9% in men [4].
All these mentioned factors of demographic change, mul-
timorbidity, high number of authorized drugs and presum-
ably rising number of polypharmacy leads to higher risks of
potentially inappropriate medications (PIMs) [6–8]. Ac-
cording to current studies, the prevalence of PIM for elderly
in Germany ranges from 22 to 28% [8–10]. There is also
evidence that the occurrence of PIM could be a risk factor
for hospitalizations or emergency department visits and
higher health care costs [11–14]. Effects of PIMs can be
manifold and occur, for example, in the form of adverse
drug events (ADE) or potential undesired drug-drug inter-
actions (PDDI) [15]. Since there are only few studies in
Germany that assessed the frequency of PDDI so far [16],
the present analysis investigates the topic of these PDDI.
The study is focused on PDDI in patients with indication
for prophylactic implantation of a cardioverter defibrillator
(ICD), which were included in the EU-CERT-ICD study
[17]. The objective was to examine the frequency of
PDDI in this specific group of patients descriptively
and to compare those patients with or without PDDI
to identify potential underlying factors.
Methods
Study design and population
The present analysis was based on data collected during
the baseline assessment within the prospective EU-
CERT-ICD study (Comparative Effectiveness Research
to Assess the Use of Primary Prophylactic Implantable
Cardioverter Defibrillators in Europe). The EU-CERT-
ICD study primarily aimed to generate contemporary
clinical outcome data on ICD effectiveness in Europe.
The study was conducted between May 2014 and Sep-
tember 2018. Patients aged ≥18 years with an ischemic
or non-ischemic (dilated) cardiomyopathy and recom-
mendation for primary prophylactic ICD treatment were
included. Patients undergoing ICD treatment were
followed as part of the ICD group, while patients who
had not received an ICD were part of the control group.
The baseline assessment for patients scheduled for an
ICD was done prior to the implantation. A detailed de-
scription of the study design and methodology of EU-
CERT-ICD is reported elsewhere [17] as well as the pri-
mary results [18]. By means of the self-reported baseline
medication data of the EU-CERT-ICD patients recruited
in Germany and Switzerland (only in these countries the
drug consumption was detailed documented by the pa-
tients itself), we performed cross-sectional analyses
about PDDI. Baseline data were used in order to reflect
the daily care routine before the study intervention
would have any influence on further treatment.
Assessment of potential drug-drug interactions
The use of regularly taken drugs prior to the onset of
the EU-CERT-ICD study was assessed by patients’ itself
and documented in a questionnaire covering the drug
consumption during the last 3 months (name of the
drug, days of intake). For these patient reported drugs,
the principal active agent was attached. PDDI can only
occur when several drugs are taken concurrently. There-
fore, a selection of those patients was made in whom at
least two drugs simultaneously have been taken for at
least 80 days (during the last 3 months) were docu-
mented. On the one hand, this limit of minimum 80 days
should ensure that the medication was taken daily and
that a tolerance range for forgetting once was consid-
ered. On the other hand, drugs that have been recently
discontinued were still included in the analysis. These
patients were defined as the population at risk.
The occurrence and the kind of PDDI was determined
using the publicly available interaction checker provided
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by drugs.com (underlying database: Cerner Multum
drug, herbal and nutraceutical database) [19]. For every
patient of the population at risk, all active substances
were entered into the interaction database of drugs.com.
According to the classification pattern provided by
drugs.com, the PDDI found were divided into three cat-
egories [19]:
 Minor: Minimally clinically significant. Minimize
risk; assess risk and consider an alternative drug,
take steps to circumvent the interaction risk and/or
institute a monitoring plan.
 Moderate: Moderately clinically significant. Usually
avoid combinations; use it only under special
circumstances.
 Major: Highly clinically significant. Avoid
combinations; the risk of the interaction outweighs
the benefit.
Substances for which no equivalent was found were
not included in the analysis. In case of multiple naming
of an active substance, this was only taken into account
once when determining the PDDI.
To characterize the study population, baseline infor-
mation about age, sex, place of residence, race and most
frequent potential comorbidities were considered.
Statistical analysis
All analyses were considered explorative. Characteristics
of patients, frequency of PDDI categories as well as the
comparison of patients with or without PDDI were ana-
lyzed using descriptive methods of means and standard
deviations for continuous data and absolute and relative
frequencies for categorical data. We performed chi
square testing for those categorical variables where the
comparison of patients with or without PDDI showed
relevant descriptive differences. All analyses were done
using SPSS for Windows (IBM SPSS Statistics 24).
Results
Characteristics of study population
The characteristics of the study population are presented
in Table 1 separately for the total population (n = 524)
and the subsample of the population at risk (n = 383)
taking ≥2 drugs daily.
Table 1 Characteristics of all patients and patients with ≥2 drugs
All patients
(n = 524)
Patients with≥ 2 drugs
(n = 383)
n (%) / Mean ± SD n (%) / Mean ± SD
Age (in years) 64.4 12.6 64.3 12.5
Sex Male 411 (78.4) 304 (79.4)
Female 113 (21.6) 79 (20.6)
Place of residence Germany 453 (86.5) 348 (90.9)
Switzerland 71 (13.5) 35 (9.1)
Race White 501 (95.6) 369 (96.3)
Black 4 (0.8) 3 (0.8)
Asian 6 (1.1) 4 (1.0)
Unknown 13 (2.5) 7 (1.8)
Number of comorbidities 0 108 (20.6) 81 (21.1)
1 194 (37.0) 143 (37.3)
2 143 (27.3) 101 (26.4)
3 66 (12.6) 46 (12.0)
4 11 (2.1) 10 (2.6)
5 2 (0.4) 2 (0.5)
Most frequent comorbidities Hypertension 359 (68.5) 260 (67.9)
Diabetes 156 (29.8) 121 (31.6)
Stroke/TIA 59 (11.3) 44 (11.5)
COPD 53 (10.1) 39 (10.2)
Peripheral arterial disease 45 (8.6) 28 (7.3)
Number of taken drugs 3.6 2.6 4.7 2.2
SD Standard deviation, TIA Transient ischaemic attack, COPD Chronic obstructive pulmonary disease
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In both populations, the mean age of the patients was
64 years and about 80% were male. The most frequent
comorbidity was hypertension with nearly 68% in both
groups followed by diabetes with about 30%. Due to ser-
ious health complaints of the study patients, the intake
of a large number of drugs was documented. A mean
number of taken drugs of 3.6 for all patients and 4.7 for
the population at risk were observed. Minimal differ-
ences between the populations were found in relation to
the place of residence of the patients. A slightly higher
proportion of patients coming from Germany were de-
tected for the population at risk (90.9%) compared to
the total study population (86.5%).
Frequency of potential drug-drug interactions
The analysis showed at least one PDDI for 296 patients
(Table 2). This corresponds to 56.5% of the total popula-
tion and 77.3% of the population at risk. The most fre-
quent PDDI category was moderate with 268 affected
patients. Major PDDIs were seen for 17.7% of the total
population and 24.3% of the population at risk. Thus, for
almost every fourth patient of our analysis who took at
least two drugs simultaneously for 80 days the risk of a
drug-drug interaction (DDI) exists. The mean number of
all PDDIs ranged from 2.3 for all patients to 3.2 for the
population at risk to 4.1 for patients with at least one
PDDI.
Comparison of patients with or without potential drug-
drug interactions
The comparison of patients with or without PDDI pro-
vided indications for possible correlating factors
(Table 3). The most relevant difference was observed for
the place of residence. The proportion of patients with
place of residence in Germany was distinctly higher for
patients with PDDI (92.9%) than for those without
(78.1%). Additionally, the mean number of taken drugs
differed considerably between patients with (5.3) and
without (1.5) PDDI. Regarding the remaining variables
of age, sex, race, number of and most frequent comor-
bidities, no or only marginal differences were found.
Comparison by country
The high differences shown previously regarding the
place of residence of patients with or without PDDI have
led to further analyses of patients from Germany com-
pared to those from Switzerland. For the total study
population, frequency of all PDDI was twice as high in
Germany as in Switzerland. Table 4 shows that 60.7% of
all German patients and 29.6% of all patients from
Switzerland had a PDDI independent from its category.
The difference decreased for the population at risk but
was still 19 percentage points. These variations of PDDI
frequency in the different places of residence appeared
to be significant according to the chi square test. For the
total study population, associations with the place of
residence were found for every PDDI category. Concern-
ing the population at risk, correlations were observed for
moderate and major PDDI. Only the frequency of minor
PDDI was not significantly related to the place of
residence. The differences in the frequency of PDDIs be-
tween both countries may be a consequence of differ-
ences in the absolute number of simultaneous taken
drugs. Figure 1 shows that patients from Switzerland
took less drugs simultaneously compared to the German
patients. The average number of daily taken drugs dif-
fered between patients from Germany and Switzerland
from 3.9 to 2.0. These differences were not alone ex-
plainable by the morbidity level, which was widely com-
parable between the patient groups (data not shown).
Discussion
Our analysis yielded high proportions of patients with a
minor, moderate or major PDDI. Any kind of PDDI was
found for just over half of all patients and just over three
quarters of patients at risk. The moderate PDDI category
was the most frequent one. Patients with and without
PDDI differed particularly concerning their place of resi-
dence, with higher proportions of PDDI in Germany. In
Table 2 Frequency of potential drug-drug interactions
Total Minor Moderate Major
Number of patients with potential drug-drug interactions
(total number of patients / percentage of patients)
n % n % n % n %
All patients (n = 524) 296 56.5 151 28.8 268 51.1 93 17.7
Patients with ≥2 drugs (n = 383) 296 77.3 151 39.4 268 70.0 93 24.3
Mean number of potential drug-drug interactions
All patients (n = 524) 2.3 0.5 1.6 0.2
Patients with ≥2 drugs (n = 383) 3.2 0.7 2.2 0.3
Patients with potential drug-drug interactions (n = 296) 4.1 0.9 2.8 0.4
Dornquast et al. BMC Health Services Research          (2020) 20:271 Page 4 of 8
addition, the average number of daily taken drugs varied
considerably between Germany and Switzerland.
However, our results are also subject to some limita-
tions. First, we have a very special and highly selected
patient clientele. Therefore, the transferability of these
results is limited. In addition, our analysis does not allow
us to make any statements as to whether any interac-
tions have actually occurred in patients with PDDI.
Moreover, this analysis was not intended to denounce
physicians in any way, but to draw attention to the prob-
lems of polypharmacy and PDDI and to sensitize people
to the problem. In addition to possible interactions,
polypharmacy also harbors other dangers. There could
be cumulative ADEs as well as a mutual intensification
of the effect of the drugs (e.g. the simultaneous use of
two blood-thinning drugs) [20].
Table 3 Characteristics of patients with or without potential drug-drug interactions
Patients without
potential drug-drug interactions (n = 228)
Patients with
potential drug-drug interactions (n = 296)
n (%) / Mean ± SD n (%) / Mean ± SD
Age 64.6 13.2 64.2 12.3
Sex Male 179 (78.5) 232 (78.4)
Female 49 (21.5) 64 (21.6)
Place of residence Germany 178 (78.1) 275 (92.9)
Switzerland 50 (21.9) 21 (7.1)
Race White 214 (93.9) 287 (97.0)
Black 3 (1.3) 1 (0.3)
Asian 2 (0.9) 4 (1.4)
Unknown 9 (3.9) 4 (1.4)
Number of comorbidities 0 43 (18.9) 65 (22.0)
1 84 (36.8) 110 (37.2)
2 69 (30.3) 74 (25.0)
3 29 (12.7) 37 (12.5)
4 3 (1.3) 8 (2.7)
5 0 (0) 2 (0.7)
Most frequent comorbidities Hypertension 161 (70.6) 198 (66.9)
Diabetes 64 (28.1) 92 (31.1)
Stroke/TIA 25 (11.0) 34 (11.5)
COPD 21 (9.2) 32 (10.8)
Peripheral arterial disease 19 (8.3) 26 (8.8)
Number of taken drugs 1.5 1.3 5.3 2.1
SD Standard deviation, TIA Transient ischaemic attack, COPD Chronic obstructive pulmonary disease
Table 4 Association between potential drug-drug interactions and place of residence by chi2-test
Potential drug-drug interactions
Total Minor Moderate Major
n % p-value n % p-value n % p-value n % p-value
All patients (n = 524)
Place of residence
Germany 275 60.7 139 30.7 250 55.2 90 19.9
Switzerland 21 29.6 < 0.001 12 16.9 0.017 18 25.4 < 0.001 3 4.2 0.001
Patients with ≥ 2 drugs (n = 383)
Place of residence
Germany 275 79.0 139 39.9 250 71.8 90 25.9
Switzerland 21 60.0 0.010 12 34.3 0.514 18 51.4 0.012 3 8.6 0.023
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Nonetheless, we are aware that in some cases poly-
pharmacy is intentionally accepted, as international stud-
ies showed positive effects and the non-administration
of drugs could have even more serious consequences
[21]. In addition, it is shown that some potential interac-
tions are only relevant for patients with a certain co-
morbidity. We did not check whether this was the case
in our population. It should also be noted that, for some
patients, the baseline data was several years old. There-
fore, it would be conceivable that certain interactions
were not known at that time, but are now listed in the
interaction database. In addition, it must be taken into
account that we used an US-American database because
of the accessibility. In comparison to German or European
ones, it is possible that other PDDIs are listed in the data-
base of drugs.com. A reason for this could be a varying
population composition regarding age or race where ac-
tive agents work differently. In addition, our assumption
that a daily intake of at least two drugs equals a concur-
rent intake is to scrutinize since we are not able to differ-
entiate the time of intake (e.g. morning, evening). This
resulting uncertainty of whether drug-drug interactions
are an issue and some other limitations listed may lead us
to overestimate the actual proportion of patients with
interactions.
The international literature regarding PDDI is quite
heterogeneous. Guthrie and colleagues reported a fre-
quency of potentially serious DDI in 13.1% of Scottish
adults in 2010 [22]. This number is rather similar to the
frequency of major PDDI (17.7%), but distinctly lower
than the value for any PDDI (56.5%) in our analyzed
population. However, Johnell and Klarin described fre-
quencies of potentially clinically relevant DDIs in 26.0%
and of potentially serious DDIs in 5.0% of elderly Swed-
ish people in 2005 [23]. A Swiss study from 2010 ob-
served a proportion of 40.0% in a cohort of HIV-infected
persons [24]. One German prospective study from 2007
analyzed patient records of an internal hospital ward
and found a proportion of 68% in patients with at least
one interacting drug combination [16]. This result is ap-
proximately comparable to our overall results of 56.5%
for all patients and 77.3% for patients with more than
two drugs respectively. Nevertheless, a direct compari-
son between the results of our present analysis and the
international published numbers remains difficult. This
may be due to the specific characteristics of our study
population, differences in health care systems or varying
study designs and assumptions. Literature concerning the
variations in the frequency of PDDI between Germany
and Switzerland could actually not be found.
Regarding possible explanations for the variations
between these two countries, differences in the aver-
age number of daily taken drugs between Swiss and
German patients were already been mentioned, but
certain other reasons would be possible. First, unlike
Germany, Switzerland has a so-called positive list of
Fig. 1 Proportion of patients and number of daily taken drugs in Germany and Switzerland
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drugs [25, 26]. Such positive list (or formulary) de-
fines a list of drugs reimbursed by a third party payer
(e.g. health insurance). Thus, presumably the number
of reimbursable drugs differs distinctly between these
two countries. Moreover, according to the Federal Insti-
tute for Drugs and Medical Devices, there are 102,754
marketable medicinal products in Germany [2]. The Swiss
Agency for Therapeutic Products reports only 8259 au-
thorized medicinal products [27]. These differences com-
bined with a fragmented health care system with a free
choice and high number of physicians may increase the
risk for PDDIs. In particular, patients with chronic dis-
eases often have a large number of different health care
providers who may prescribe drugs without knowing of
already taken medications. In Germany, the pharmacists
should actually check whether there are interactions
(probably not systematic) between prescribed drugs. How-
ever, they only see the drugs on the specific prescription
and know nothing about already taken medications. Over-
all it seems to be indicated to take measures that lead to
improved information transparency for drug prescriber,
pharmacists and patients (e.g. digital patient files). Bergk
and colleagues already developed suggestions concerning
more access for general practitioners or specialists to drug
interaction information systems in 2004 [28]. Such sys-
tems could give information on PDDI, their clinical rele-
vance, but also patient characteristics and management
recommendations based on them [29].
Conclusions
In this highly selected patient population, a reasonably large
proportion of PDDIs was observed. The rates varied be-
tween the three categories with highest values for moderate
PDDIs. Largest descriptive differences in patients with or
without any PDDI were found regarding their place of resi-
dence. The presented results are intended to raise aware-
ness of the risks of polypharmacy and PDDIs. Especially for
older patients with a high number of comorbidities and
prescribed medications, it is important to keep this problem
in mind. Adequate cooperation between the various health
care providers and new technologies in the health care sec-
tor can help to minimize these risks.
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